Tyrosine kinase inhibitors (TKI): dasatinib
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Tyrosine kinase inhibitors (TKI): dasatinib. Demyelinating peripheral neuropathy: this is reversible. Fully referenced neurology checklist.
Neurological complications
- Demyelinating peripheral neuropathy: this is reversible
- Optic neuropathy
- Rhabdomyolysis
- Cognitive impairment
- Inclusion body myositis (IBM)
Pulmonary complications
Locked: subscribe to see this section.
Cardiovascular complications
Locked: subscribe to see this section.
Renal complications
Locked: subscribe to see this section.
Gastrointestinal complications
Locked: subscribe to see this section.
Dermatological complications
Locked: subscribe to see this section.
Haematological complications
Locked: subscribe to see this section.
Other complications
Locked: subscribe to see this section.
References
- Inoue H, Taji H, Yamada K, et al. Dasatinib-induced reversible demyelinating peripheral neuropathy and successful conversion to nilotinib in chronic myelogenous leukemia. Intern Med 2020; 59:2419-2421.
- Ishida T, Akagawa N, Miyata T, et al. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia. Int J Hematol 2018; 107:373-377.
- Monge KS, Gálvez-Ruiz A, Alvárez-Carrón A, Quijada C, Matheu A. Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol 2015; 29:227-231.
- Joel Chandranesan AS, Master S, Antosz O, PeytonThomas B, Koshy N. Dasatinib-induced rhabdomyolysis in a 33-year-old patient with chronic myeloid leukemia. Case Rep Hematol 2018; 2018:2849869.
- Chamoun K, Rabinovich E, Baer L, Fastenau P, Lima M. A case of neurocognitive deficit strongly related to dasatinib therapy. Hematol Transfus Cell Ther 2020; 42:80-82.
- And 38 more. Subscribe to see the full list
